Back to drug

The Drug-Induced Respiratory Disease Website and App

Frequency - Incidence

Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases

Evidence level/grade

Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic

I.z

An area or areas of consolidation

Publications

Huang PH, Kuo CJ, Lin CW, Cheng YM, Hu HC, Lin CY, Su MY, Chiu CT

Mesalazine-related lung disease in a patient with ulcerative colitis: A case report.

Medicine. 2018;97(48):e13242

Wang IJ, Lin CC, Lin YJ, Hsieh WS, Chen PC

Early life phthalate exposure and atopic disorders in children: a prospective birth cohort study.

Environment international. 2014;62:48-54

Kim JH, Lee JH, Koh ES, Park SW, Jang AS, Kim D, Park CS

Acute eosinophilic pneumonia related to a mesalazine suppository.

Asia Pacific allergy. 2013;3(2):136-9

Kevans D, Greene J, Galvin L, Morgan R, Murray FE

Mesalazine-induced bronchiolitis obliterans organizing pneumonia (BOOP) in a patient with ulcerative colitis and primary sclerosing cholangitis.

Inflammatory bowel diseases. 2011;17(10):E137-8

Camus P, Piard F, Ashcroft T, Gal AA, Colby TV

The lung in inflammatory bowel disease.

Medicine. 1993;72(3):151-83